

NECLIFE PT, UNIPESSOAL LDA.

Registered Office: Rua Brito Pais, 8C, 1495-028Algés
PORTUGAL
Telephone: +351 218863595, Fax: +351 218863595
e-mail ID : nectar.uk@neclife.com



Directors' Report
For the year ended 31 March 2023

The directors present their annual report and financial statements for the year ended 31 March 2023.

Principal activities

The company has not traded during the year.

Directors/ Managers

During the financial year 2022-23, Dr, Dinesh Dua, ceased to be a director/ manager and in his place, Mr. Amit Chadah has been appointed. The directors/ managers who held office during the year and up to the date of signature of the financial statements were as follows:


Mr. Amit Chadah
Nectar Lifesciences Limited

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies' exemption.

Audit

Neclife PT, Unipessoal LDA, being a privately held company, is not required to get its financial statement audited for the financial year ended on March 31, 2023 under any law of Portugal.

For Neclife PT, Unipessoal LDA



(Amit Chadah)
Manager/ Director

Date: 17-04-2023

Neclife PT, Unipessoal LDA – Portugal
Balance Sheet as at March 31, 2023

Assets	Note	31-Mar-23	31-Mar-22
Cash & Cash Equivalents			
Cash & Bank Balances	3	€ 1,000	€ 1,000
Total		€ 1,000	€ 1,000
Liabilities			
Shareholder's Fund			
Share Capital	4	€ 1,000	€ 1,000
Total		€ 1,000	€ 1,000

For Neclife PT, Unipessoal LDA



(Amit Chadah)
Manager/Director

Date: 17.04.2023

NECLIFE PT, UNIPessoal LDA.

Registered Office: Rua Brito Pais, 8C, 1495-028Algés
PORTUGAL
Telephone: +351 218863595, Fax: +351 218863595
e-mail ID : nectar.uk@neclife.com



Notes to Financial Statements For the year ended March 31, 2023

1. Accounting Policies

1.1 Accounting Conventions

The financial statements are prepared under the historical cost convention. The principal accounting policies adopted are set out below.

The financial statements are prepared in Euros, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest euro.

1.2 Profit & Loss Account

The company has not traded during the year. During this time the company received no income and incurred no expenditure and therefore no profit & loss account is presented in these financial statements.

1.3 Equity Instruments


Equity instruments issued by the company are recorded at the proceeds received, net of direct issue costs. Dividends payable (if any) on equity instruments are recognized as liabilities once they are no longer at the discretion of the company.

2. Parent Company

The parent company is Nectar Lifesciences Limited, a company registered in India, by the virtue of its 100% shareholding in the company. There is no ultimate controlling party of Nectar Lifesciences Limited.

Consolidated group accounts are being prepared by Nectar Lifesciences Limited. These can be obtained from the registered office: Village Saidpura, Tehsil Derabassi, Distt. S.A.S. Nagar (Mohali), Punjab, India.

For Neclife PT, Unipessoal LDA


(Amit Chadah)
Manager/ Director

Date: 17-04-2023

Neclife PT, Unipessoal LDA – Portugal

Cash & Cash Equivalents

Note - 3


Particulars	31-Mar-23	31-Mar-22
Cash & Bank Balance	€ 1,000	€ 1,000
Total	€ 1,000	€ 1,000

Share Capital

Note - 4

Particulars	31-Mar-23	31-Mar-22
Issued and paid up share capital	€ 1,000	€ 1,000
Total	€ 1,000	€ 1,000

For Neclife PT, Unipessoal LDA


(Amit Chadah)
Manager/Director

Date: 17.04.2023